Skip to main content
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. — Investor Relations & Filings

Ticker · LYEL ISIN · US55083R1041 US Manufacturing
Filings indexed 291 across all filing types
Latest filing 2025-08-13 Regulatory Filings
Country US United States of America
Listing US LYEL

About Lyell Immunopharma, Inc.

https://lyell.com/

Lyell Immunopharma, Inc. is a clinical-stage cell therapy company that develops Chimeric Antigen Receptor (CAR) T-cell therapies for cancer. The company pioneers T-cell reprogramming technologies designed to overcome the primary barriers to durable clinical responses in patients. Its scientific approach focuses on enhancing T-cell function and fitness to improve the efficacy and persistence of its therapeutic candidates. Lyell's pipeline targets both solid tumors and hematologic malignancies, addressing significant unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-08-13 English
S-3
Regulatory Filings
2025-08-12 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-12 English
8-K
Regulatory Filings
2025-08-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-01 English
424B5
Regulatory Filings
2025-07-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.